This recombinant monoclonal antibody is a research-grade biosimilar to ABP-692, designed to target MS4A1 (Membrane Spanning 4-Domains A1), also known as CD20. MS4A1 is a cell surface phosphoprotein exclusively expressed on B lymphocytes from the pre-B to mature B-cell stages, playing a crucial role in B-cell development, activation, and calcium influx regulation. This protein serves as an important marker for B-cell lineage and is implicated in various B-cell malignancies including non-Hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune disorders such as rheumatoid arthritis and multiple sclerosis.
ABP-692 is a rituximab biosimilar reference antibody that binds specifically to the CD20 antigen on B cells. This biosimilar antibody provides researchers with a valuable tool for investigating B-cell biology, studying mechanisms of B-cell depletion, exploring therapeutic targets in hematological cancers, and examining autoimmune disease pathogenesis. It supports applications in oncology research, immunology studies, and therapeutic antibody development programs.
Email: support@cusabio.com
Distributors Worldwide